AU2013365739A1 - Tricyclic compounds for inhibiting the CFTR channel - Google Patents

Tricyclic compounds for inhibiting the CFTR channel Download PDF

Info

Publication number
AU2013365739A1
AU2013365739A1 AU2013365739A AU2013365739A AU2013365739A1 AU 2013365739 A1 AU2013365739 A1 AU 2013365739A1 AU 2013365739 A AU2013365739 A AU 2013365739A AU 2013365739 A AU2013365739 A AU 2013365739A AU 2013365739 A1 AU2013365739 A1 AU 2013365739A1
Authority
AU
Australia
Prior art keywords
dimethyl
dione
pyrimido
pyrrolo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013365739A
Other languages
English (en)
Inventor
Mahbub AHMED
Alexander ASHALL-KELLY
Louisa GUERITZ
Jeffrey Mckenna
Joseph Mckenna
Simon MUTTON
Rakesh PARMAR
Jon SHEPHERD
Paul Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013365739(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013365739A1 publication Critical patent/AU2013365739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013365739A 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the CFTR channel Abandoned AU2013365739A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US61/739,335 2012-12-19
US201361906141P 2013-11-19 2013-11-19
US61/906,141 2013-11-19
PCT/IB2013/061043 WO2014097148A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the cftr channel

Publications (1)

Publication Number Publication Date
AU2013365739A1 true AU2013365739A1 (en) 2015-07-09

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013365739A Abandoned AU2013365739A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the CFTR channel

Country Status (25)

Country Link
US (2) US20140171417A1 (enExample)
EP (1) EP2935278B1 (enExample)
JP (1) JP6284546B2 (enExample)
KR (1) KR20150097660A (enExample)
CN (1) CN105143230B (enExample)
AP (1) AP2015008539A0 (enExample)
AR (1) AR094122A1 (enExample)
AU (1) AU2013365739A1 (enExample)
BR (1) BR112015014292A2 (enExample)
CA (1) CA2895660A1 (enExample)
CL (1) CL2015001730A1 (enExample)
CR (1) CR20150325A (enExample)
CU (1) CU20150066A7 (enExample)
EA (1) EA201591177A1 (enExample)
ES (1) ES2628369T3 (enExample)
HK (1) HK1209741A1 (enExample)
IL (1) IL239389A0 (enExample)
MX (1) MX2015007939A (enExample)
PE (1) PE20151055A1 (enExample)
PH (1) PH12015501386A1 (enExample)
SG (1) SG11201504594QA (enExample)
TN (1) TN2015000279A1 (enExample)
TW (1) TW201429974A (enExample)
UY (1) UY35211A (enExample)
WO (1) WO2014097148A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
CN105143230B (zh) 2012-12-19 2017-06-09 诺华股份有限公司 用于抑制cftr通道的三环化合物
EA201591175A1 (ru) * 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr
TWI686429B (zh) 2014-09-19 2020-03-01 美商摩曼帝夫特性材料公司 用於經控制之矽氧烷交聯的鉑(ii)二烯錯合物
HUE054399T2 (hu) * 2015-04-23 2021-09-28 Trevi Therapeutics Inc Vegyületek viszketéses állapotok kezelésére
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
EP3911649A1 (en) * 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG A process for the preparation of tetrahydropyridopyrimidines
JP7669295B2 (ja) * 2019-06-12 2025-04-28 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 胆汁酸性下痢を治療する方法
WO2022232634A1 (en) 2021-04-29 2022-11-03 Novartis Ag Deubiquitinase-targeting chimeras and related methods
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60025616T2 (de) 1999-08-25 2006-11-30 Banyu Pharmaceutical Co., Ltd. Isoindolderivate
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20090087487A (ko) 2006-12-12 2009-08-17 쉐링 코포레이션 아스파르틸 프로테아제 억제제
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011019737A1 (en) * 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2012166658A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
CN105143230B (zh) 2012-12-19 2017-06-09 诺华股份有限公司 用于抑制cftr通道的三环化合物
EA201591175A1 (ru) * 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr

Also Published As

Publication number Publication date
WO2014097148A1 (en) 2014-06-26
CN105143230B (zh) 2017-06-09
UY35211A (es) 2014-07-31
PH12015501386A1 (en) 2015-09-02
CR20150325A (es) 2015-08-10
IL239389A0 (en) 2015-07-30
CN105143230A (zh) 2015-12-09
SG11201504594QA (en) 2015-07-30
KR20150097660A (ko) 2015-08-26
HK1209741A1 (en) 2016-04-08
EP2935278B1 (en) 2017-03-15
EA201591177A1 (ru) 2015-11-30
CU20150066A7 (es) 2015-11-27
JP6284546B2 (ja) 2018-02-28
ES2628369T3 (es) 2017-08-02
BR112015014292A2 (pt) 2017-07-11
AP2015008539A0 (en) 2015-06-30
WO2014097148A9 (en) 2015-02-19
PE20151055A1 (es) 2015-08-05
MX2015007939A (es) 2016-03-11
TN2015000279A1 (en) 2016-10-03
US20150336986A1 (en) 2015-11-26
CL2015001730A1 (es) 2015-08-28
JP2016509579A (ja) 2016-03-31
TW201429974A (zh) 2014-08-01
US9359381B2 (en) 2016-06-07
CA2895660A1 (en) 2014-06-26
AR094122A1 (es) 2015-07-08
US20140171417A1 (en) 2014-06-19
EP2935278A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
AU2013365739A1 (en) Tricyclic compounds for inhibiting the CFTR channel
JP6629847B2 (ja) 縮合五員環イミダゾール誘導体
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
CA2976294A1 (en) Preparation of tricyclic compounds as farnesoid x receptor modulators and their application to treat related diseases
BR112016011851B1 (pt) Derivados de imidazol e pirazol fundidos como moduladores de atividade de tnf
EP2935277B1 (en) Tricyclic compounds as cftr inhibitors
EP3390404A1 (en) Tricyclic compounds and compositions as kinase inhibitors
WO2025212729A1 (en) Macrocyclic compounds and their use
HK1244279B (en) Tricyclic compounds and uses thereof in medicine
HK1240916B (en) Fused pentacyclic imidazole derivatives
UA113436C2 (xx) 4-(ЗАМІЩЕНІ АМІНО)-7H-ПІРОЛО[2,3-d]ПІРИМІДИНИ ЯК ІНГІБІТОРИ LRRK2

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted